Pharma major Lupin has entered a strategic licensing agreement to manufacture and commercialize injectable Semaglutide, a leading therapy for type 2 diabetes, positioning itself to capitalize on the rapidly growing global diabetes treatment market. The deal aligns with Lupin’s broader strategy to strengthen its specialty care portfolio while leveraging its manufacturing and regulatory expertise. Analysts suggest this move could drive revenue growth, diversify product offerings, and enhance the company’s presence in high-margin therapeutic areas.
